
|Articles|March 18, 2006
Novel anti-collagenolytic regimen applied for treating stage IV DLK
A new treatment strategy consisting of oral doxycycline and topical sodium citrate 10% may have a positive role in the treatment of post-LASIK inflammatory conditions characterized by increased collagenolytic activities, said Elias F. Jarade, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
PainReform launches development plan for OcuRing-K, readies phase 2 trial
4
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
5















































.png)


